ASCO 2022 | DESTINY-Breast04: practice-changing results for HER2-low breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, speaks on the practice-changing findings from DESTINY-Breast04 (NCT03734029), a Phase III study that demonstrated improved survival of patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan compared to standard chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.